| INTRODUCTION
Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) with typical chronic relapsing and remitting disease course, 1 affecting an increasing proportion of the population in the USA. 2, 3 While potentially debilitating if improperly treated, 4 recent developments in biologic therapies have significantly improved health outcomes in IBD. Expensive, yet effective, biologics are a mainstay of medical therapy options for disease maintenance in both CD and UC. 5 As a result of increasing biologics use, overall costs of medical care have shifted from acute care services to out-patient pharmacy utilization, 6 with recent evidence suggesting pharmacy costs account for nearly one-half of all disease-related direct expenditures. [7] [8] [9] This trend in prescription drug costs outpacing all other segments of healthcare is consistent across other chronic diseases. 10, 11 Compared to other medication classes, namely 5-ASAs, immunomodulators (mercaptopurine, azathioprine, and methotrexate), and corticosteroids, biologics use represents an increasing impact to rising health care costs in IBD. Traditional biologics, consisting of anti-tumor necrosis factor alpha (anti-TNF) agents such as adalimumab and infliximab, drive the biologic market, but newer agents such as vedolizumab and ustekinumab are increasingly used in clinical practice.
It is not known how the overall out-patient pharmaceutical drug market has evolved in recent years given increasing use of biologics.
Therefore, in today's "Era of Biologics," determining cost-effective strategies for biologics in the USA remains a major knowledge gap. 
| Prescription drug identification
To capture drug utilization of out-patient medications for IBD, we examined patients who had at least one pharmaceutical claim or out-patient infusion/injection for a biologic medication (adalimumab, certolizumab pegol, golimumab, infliximab, natalizumab, vedolizumab, ustekinumab), immunomodulator (azathioprine, mercaptopurine, methotrexate sodium), 5-ASA (mesalazine, sulfasalazine), or oral corticosteroid (prednisone or prednisolone).
| Assignment of maintenance medication
To examine the market share of patients' primary IBD medication, we followed a hierarchical system to classify patients receiving more than one medication (e.g. combination therapy using biologics and assigned to the corticosteroid category, and we assumed that these patients were not on an appropriate IBD maintenance medication.
| Statistical analysis
All descriptive statistical analyses were performed using STATA 14.2 (College Station, TX). Means, median, and standard deviations for PMPY costs in 2017 dollars were calculated.
3 | RESULTS Another interesting finding in our analysis is that biologics' market share in paediatric patients outpaces the market share in all patients. Paediatric patients also had less corticosteroid-only maintenance therapy. This may reflect the known phenotypic difference between adult-vs paediatric-onset IBD. 19 Children with IBD often present with worse disease severity requiring early biologics use as first-line maintenance therapy. 13 Although outside the scope of this study, proactive out-patient IBD care with the treatment goal of corticosteroid-free remission may be more nationally standardized and implemented in paediatric IBD care models. Inherent to large database analyses, we acknowledge that our find- 
| Summary of patients
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In summary, our analysis uniquely explores the cost impact of increasing biologics use from out-patient IBD care in the USA. The findings from our study further reiterate the ongoing need to develop patient-centred, cost-effective pharmacotherapy strategies by judiciously incorporating biologics in individualized therapy plans.
